<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216982</url>
  </required_header>
  <id_info>
    <org_study_id>M-10023</org_study_id>
    <nct_id>NCT01216982</nct_id>
  </id_info>
  <brief_title>Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders</brief_title>
  <official_title>Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders: A Mood Resilience Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>United States Department of Defense</source>
  <brief_summary>
    <textblock>
      Stress-related disorders are among the most prevalent and expensive medical consequences of
      participation in military operations. Omega-3 fatty acids EPA/DHA derived from fish oil are
      known to benefit both neuronal development in the young, and cognition and mood in various
      populations.

      It is possible that soldiers receiving Omega-3 EPA/DHA will exhibit significantly higher
      cognitive performance, better affect/mood state, and less combat stress symptomatology
      compared to the placebo after 12 weeks of supplementation. A goal would be to reduce the
      prevalence of combat stress injuries in military personnel.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary psychometric assessment battery</measure>
    <time_frame>3 months</time_frame>
    <description>Specific components include:
Zung Depression Scale (ZDS) Zung Anxiety Scale (ZAS) Pittsburgh Sleep Quality Index (PSQI) Epworth Sleepiness Scale (ESS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>omega-3 fatty acid status</measure>
    <time_frame>3 months</time_frame>
    <description>finger-prick blood spot is collected for determination of fatty acid composition and profile.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary psychometric assessment battery</measure>
    <time_frame>3 months</time_frame>
    <description>This battery will generate index scores in the area of:
Memory, Psychomotor Speed, Reaction Time, Cognitive Flexibility, and Complex Attention. It will also include the Alcohol Use Identification Test (AUdIT). Military-specific components include Post-Deployment Health Assessment (PDHA), Neurobehavioral Symptom Inventory (NSI), Combat Exposure Scale (CES), and parts of the Deployment Risk and Resilience Inventory (edited).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Mood Disorders</condition>
  <condition>Depression</condition>
  <condition>Combat Disorders</condition>
  <condition>Stress Disorders</condition>
  <arm_group>
    <arm_group_label>Lovaza, omega-3 fatty acid ethyl ester</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one gram corn oil in a soft gelatin capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza, omega-3 fatty acid ethyl ester</intervention_name>
    <description>Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day</description>
    <arm_group_label>Lovaza, omega-3 fatty acid ethyl ester</arm_group_label>
    <other_name>LOVAZA 1g Soft Gelatin Capsules NDC NO. 65726-425-15</other_name>
    <other_name>Omega-3-Acid Ethyl Esters</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, visually identical to Lovaza</intervention_name>
    <description>Three 1g corn oil capsules/day for three months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corn oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  US Army deployed personnel

          -  score on a mood questionnaire

        Exclusion Criteria:

          -  currently consume omega-3 fish oil supplements

          -  are currently taking antidepressant or other medications for psychiatric purposes

          -  pregnant

          -  known fish or shellfish allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel T Johnston, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Department of Defense</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Military Base</name>
      <address>
        <city>Camp Taji</city>
        <zip>09378</zip>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>March 8, 2011</last_update_submitted>
  <last_update_submitted_qc>March 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Daniel T. Johnston, MD, MPH, LTC, US Army MC,</name_title>
    <organization>1st CAB, US ARMY</organization>
  </responsible_party>
  <keyword>Mood Disorders</keyword>
  <keyword>Depression</keyword>
  <keyword>Combat Disorders</keyword>
  <keyword>Stress Disorders</keyword>
  <keyword>Fatty Acids, Omega-3</keyword>
  <keyword>Military Personnel</keyword>
  <keyword>Docosahexaenoic Acids/*therapeutic use</keyword>
  <keyword>Eicosapentaenoic Acid/*therapeutic use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Combat Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

